Cargando…

Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy

Multidrug resistance (MDR) is a significant problem in the treatment of cancer. Chemotherapeutic drugs distribute through the cyto- and nucleoplasm of drug-sensitive cells but are excluded from the nucleus in drug-resistant cells, concentrating in cytoplasmic organelles. Weak base chemotherapeutic d...

Descripción completa

Detalles Bibliográficos
Autores principales: Altan, Nihal, Chen, Yu, Schindler, Melvin, Simon, Sanford M.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212293/
https://www.ncbi.nlm.nih.gov/pubmed/9584137
_version_ 1782148664952619008
author Altan, Nihal
Chen, Yu
Schindler, Melvin
Simon, Sanford M.
author_facet Altan, Nihal
Chen, Yu
Schindler, Melvin
Simon, Sanford M.
author_sort Altan, Nihal
collection PubMed
description Multidrug resistance (MDR) is a significant problem in the treatment of cancer. Chemotherapeutic drugs distribute through the cyto- and nucleoplasm of drug-sensitive cells but are excluded from the nucleus in drug-resistant cells, concentrating in cytoplasmic organelles. Weak base chemotherapeutic drugs (e.g., anthracyclines and vinca alkaloids) should concentrate in acidic organelles. This report presents a quantification of the pH for identified compartments of the MCF-7 human breast tumor cell line and demonstrates that (a) the chemotherapeutic Adriamycin concentrates in acidified organelles of drug-resistant but not drug-sensitive cells; (b) the lysosomes and recycling endosomes are not acidified in drug-sensitive cells; (c) the cytosol of drug-sensitive cells is 0.4 pH units more acidic than the cytosol of resistant cells; and (d) disrupting the acidification of the organelles of resistant cells with monensin, bafilomycin A1, or concanamycin A is sufficient to change the Adriamycin distribution to that found in drug-sensitive cells, rendering the cell vulnerable once again to chemotherapy. These results suggest that acidification of organelles is causally related to drug resistance and is consistent with the hypothesis that sequestration of drugs in acidic organelles and subsequent extrusion from the cell through the secretory pathways contribute to chemotherapeutic resistance.
format Text
id pubmed-2212293
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-22122932008-04-16 Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy Altan, Nihal Chen, Yu Schindler, Melvin Simon, Sanford M. J Exp Med Article Multidrug resistance (MDR) is a significant problem in the treatment of cancer. Chemotherapeutic drugs distribute through the cyto- and nucleoplasm of drug-sensitive cells but are excluded from the nucleus in drug-resistant cells, concentrating in cytoplasmic organelles. Weak base chemotherapeutic drugs (e.g., anthracyclines and vinca alkaloids) should concentrate in acidic organelles. This report presents a quantification of the pH for identified compartments of the MCF-7 human breast tumor cell line and demonstrates that (a) the chemotherapeutic Adriamycin concentrates in acidified organelles of drug-resistant but not drug-sensitive cells; (b) the lysosomes and recycling endosomes are not acidified in drug-sensitive cells; (c) the cytosol of drug-sensitive cells is 0.4 pH units more acidic than the cytosol of resistant cells; and (d) disrupting the acidification of the organelles of resistant cells with monensin, bafilomycin A1, or concanamycin A is sufficient to change the Adriamycin distribution to that found in drug-sensitive cells, rendering the cell vulnerable once again to chemotherapy. These results suggest that acidification of organelles is causally related to drug resistance and is consistent with the hypothesis that sequestration of drugs in acidic organelles and subsequent extrusion from the cell through the secretory pathways contribute to chemotherapeutic resistance. The Rockefeller University Press 1998-05-18 /pmc/articles/PMC2212293/ /pubmed/9584137 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Altan, Nihal
Chen, Yu
Schindler, Melvin
Simon, Sanford M.
Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy
title Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy
title_full Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy
title_fullStr Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy
title_full_unstemmed Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy
title_short Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy
title_sort defective acidification in human breast tumor cells and implications for chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212293/
https://www.ncbi.nlm.nih.gov/pubmed/9584137
work_keys_str_mv AT altannihal defectiveacidificationinhumanbreasttumorcellsandimplicationsforchemotherapy
AT chenyu defectiveacidificationinhumanbreasttumorcellsandimplicationsforchemotherapy
AT schindlermelvin defectiveacidificationinhumanbreasttumorcellsandimplicationsforchemotherapy
AT simonsanfordm defectiveacidificationinhumanbreasttumorcellsandimplicationsforchemotherapy